Rhythm Biosciences (ASX:RHY) said that its Genetype business recorded its first commercial sales under the company's ownership, according to a Wednesday Australian bourse filing.
The company said it is forecasting an "attractive" sales growth profile for Genetype products over the foreseeable future, driven by potential enterprise customers and support from influential key opinion leaders, among other factors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.